American Pharmaceutical Giant Pfizer Pharmaceutical Co., Ltd. (PFIZER) acquired the desire of British pharmaceutical giant Astrazeneca，It has not been eliminated because of the latter's rejection。

 

 

 

According to a report from London on May 2nd, Reuters，Pfizer said on the same day，The acquisition quotation of Astraikon has been raised to 63 billion pounds (about $ 106 billion)，I hope to be the basis for the merger of both parties to discuss mergers，It is also said that Astraikon is evaluating the proposal。

 

 

 

The offer is equivalent to £ 50 per share (about $ 84.47)。Earlier this week，Astrikon rejected Pfizer's offer to its valuation of $ 98.9 billion，Tightly £ 46.61 per share。

 

 

 

Reuters of the above Reuters report，Pfizer said，Astrikon said that he will make a reply after his board evaluating the latest acquisition proposal。According to Pfizer's offer，Aslekang's shareholder will receive 1.854 shares of the company's shares and £ 15.98 cash。

 

 

 

Yesterday's Wall Street Journal reported，Restore negotiation means that the two parties may take a step in a goodwill acquisition transaction，However, whether it can be reached in the end is still uncertain。

 

 

 

If Pfizer and Astrikon finally reached an M & A agreement，It will create the world's largest pharmaceutical company，The types of drugs sold by the company after the merger will cover the cancer、Most diseases including diabetes and heart disease。

 

 

 

but but，The news came out yesterday evening，Astrikang's board of directors has rejected Pfizer's latest purchase price worth $ 106 billion，The board believes that Pfizer’s latest merger proposal is insufficient。

 

 

 

According to the British Stake Sports BettingM Stake Sports Betting& A regulations，Pfizer's latest proposal to propose a formal acquisition of Astraon on May 26，Otherwise, it should be announced to give up the purchase intention。

 

 

 

I was rejected a week ago

 

 

 

April 28th, April 28th, a week ago，Pfizer confirmed that it is seeking mergers and acquisitions of Astraika。According to the announcement，April 26，Pfizer once again proposed the acquisition intention to Astrikang，But Astrikan believes that Pfizer's offer seriously underestimate its value and refuse to negotiate。

 

 

 

Pfizer also said，January 5 this year，It has proposed to acquire Astraikon for 58.8 billion pounds ($ 98.9 billion)，But the negotiation ended on January 14。According to the acquisition proposal in January，Pfizer plans to acquire Astraikon with cash plus stocks，Valuation of Astraikon is 46.61 pounds per share (about $ 76.62)，The premium at that time was about 30%。This news makes Astrakang's stock price soared 15%after the opening of April 28，Newspaper 78.94 US dollars，Valuation exceeds 100 billion US dollars。

 

 

 

The acquisition intention issued by Pfizer，Astrikang issued a statement on April 28，CEO of Pfizer (CEO) Ian & Middot; Ianream (Ianread) in contact with Astraika，No specific proposal，& ldquo; There is no specific and attractive solution to propose before & rdquo;，I will not discuss with Pfizer on the acquisition problem。

 

 

 

Astrikon emphasized to shareholders in this statement，I have confidence in the execution of Astraikon's strategy as a independent company，& ldquo; strong recommendation & rdquo; Shareholders do not take action on Pfizer's approach。

 

 

 

Previous April 24，CEO Pascalsoriot, Chief Executive CEO of Asley Kang, said when the company released a quarterly report，Strong and strong combination can sometimes achieve expected goals，but usually it is destructive，Another，For transactions like GSK (Glaxo Sonsk) and Novartis's business swap，Astrikang will also consider。

 

An senior person in a pharmaceutical company once analyzed the Morning Post reporter，Pfizer is the best company in pharmaceutical companies，Such a high -profile disclosure to the acquisition intention，Explanation will not give up this transaction easily，Maybe you may use & ldquo; hostile acquisition & rdquo;，also known as forced acquisition)，Just like the acquisition of Warnerlambert (warnerlambert) at that time，At that time, the company's M & A negotiations with Wyeth was close to the end。

 

 

 

February 2000，Well & Middot; Langbert initially Stake Sports Bettingaccepted stake online sports bettingPfizer's hostility，Acquisition is performed in the form of stock exchange，involved in funds of $ 85 billion，Pfizer after the merger becomes the largest pharmaceutical factory in the United States。In addition，2002，Pfizer acquired the Famasian Pharmaceutical Factory for $ 60 billion; in 2009, Pfizer acquired competitors Wyeth，The total price of the transaction is about $ 68 billion。

 

 

 

Astrikan is the second largest pharmaceutical group in the UK，Digestion、Cardiovascular、Central nervous nervous、Breathing、Tumor、Anesthesiology and anti -infection has several important disease fields with multiple heavyweight prescription medicines。but，Because the company's patents of several best -selling drugs are about to expire，Its future growth prospects are full of variables。In the past three years，Astrikang's sales dropped from US $ 33.6 billion to $ 25.7 billion。Some analysts expect more drugs to lose patent protection，In the future, the company's loss will also expand。

 

 

 

If you successfully acquire Astrikan，Pfizer's anti -cancer drug portfolio will be enhanced，and can save a lot of cost and tax burden。Pfizer will get experimental anti -cancer therapy，Also known as immunotherapy (by improving the body's immune system function to fight tumor)，The pharmaceutical industry believes that this will be the next mainstream of the market with rich profits.。The aforementioned person said，Under the circumstance when a large number of heavy drugs expire，M & A for the supplementary value of Pfizer's product line is self -evident。Another point to pay attention to is，Acquisition can use a large amount of cash accumulated by Pfizer's subsidiaries outside the United States，These funds will be returned to the United States and will be counted as heavy tax。

 

 

 

According to the data released by the research company Auditanalytics，Pfizer's overseas cash has reached 69 billion US dollars。

 

 

 

The above Wall Street Journal reports quoted the hint of Pfizer managers，Some cash reserves that the company earns and reserved abroad will be used to pay the funds required for the acquisition。

 

 

 

Pfizer lobby British government

 

 

 

Although Pfizer asked for aslocked for Asley，But this acquisition has caused political disputes in the UK，Because of this transaction is expected to become the largest case for British companies to be acquired by foreign companies。There is news，Some British lawmakers expressed their opposition to Pfizer's purchase proposal earlier this week，Observed My stake betting appthat stake sports betting appgovernment departments must obtain Pfizer's guarantee for employment and research investment。

 

 

 

According to Reuters report，To reduce the concerns of the British government，Ian & Middot; Reed to British Prime Minister Cameron，Promise will complete the large -scale research and development center of the Astrikon plan in Cambridge, England，and retain a manufacturing plant in MacClesField。Ian & Middot; Reed also said，After the merger, the company will deploy 20%of R & D personnel in the UK。

 

 

 

Another news，Ian & Middot; Reed met with a number of British government ministers on April 29，Discuss possible acquisitions。He emphasized when meeting，The company plans to continue research and development and manufacturing in the UK，And will choose to register under the British tax system。

 

 

 

Wall Street Journal yesterday quoted Pfizer managers' words，Pfizer will put the registered company of the merged company in the UK，To reduce the company's tax rate。The manager also said，It is expected that the company will cut costs after merging。

 

 

 

The news came out last night，A spokesman for British Prime Minister Cameron said，The two companies of the United Kingdom and Pfizer and Astrikan have maintained contact，It is also said that Pfizer's decision to acquire Astraon is for business purposes。

 

 

 

It is worth mentioning that it is，Pfizer's acquisition plan，It may face antitrust censorship in China。Because，Pfizer and Astrikang's two companies in the prescription drug market in China，Locate the largest and second largest international supplier。

 

 

 

According to a source of information quoted by Reuters, it is said，This mergers and acquisitions must be obtained in addition to obtaining antitrust permits from the United States and Europe，It must also pass the approval of China，It may be delayed because of this。Julianhuppert said，China may be severely tried in this case，Especially in a scandal that had a drug company Grandulsc in last year。

 

 

 

& ldquo; I know that China has doubts about this。From the perspective of China，This involves the combination of the two major suppliers in the Chinese market as one，In view of the experience of contact with GlaxoSmiths in the past，There are indeed some obvious doubts。& rdquo; Huppert said to Reuters。

 

 

 

Currently for Pfizer，Get Astrikang's & ldquo; nod & rdquo;，is the key step of the acquisition。

 

 

 

Before the news of Astrikang's board of directors last night, the news that the board of directors had rejected the latest acquisition price，The opinion of the news quoted German Bank，stake online sports bettingThe stake betting appincrease in price after raising is still not enough to ensure that the agreement is reached。

 

 

 

German Bank pointed out，The new price is about 7%higher than the acquisition price proposed in January，I believe Pfizer needs to increase cash as a price。Another，Investment company Panmuregordon said，The purchase price of 50 pounds per share may attract investors，But the purchase price may be further increased to nearly 55 pounds per share。

 

 

 

Pfizer this huge acquisition plan，It is expected to add a series of mergers and acquisitions for the global medical care industry this year。

 

 

 

Thomson Reute data display，After a series of mergers and acquisitions appeared in the health care industry，The world's M & A transactions have exceeded $ 1 trillion in this year，For the third time since 1980, the data has exceeded $ 1 trillion in the data。M & A transactions that have occurred in the healthcare industry this year include: Zimmer proposed to acquire plastic surgery product manufacturers Biomet for $ 13.35 billion;，For more than 20 billion US dollars asset exchange。The trading that is happening includes: Germany Bayer seek to sell its plastic department worth $ 10 billion; the United States Merck wants to sell the consumer medical insurance department's business for $ 14 billion。